Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Glioblastoma
is one of the most malignant tumors in the brain with high mortality. In recent years, immunotherapy and targeted therapy show great prospects in the treatments for
glioblastoma
, whereas more effective therapeutic targets are still urgently needed to be developed.
Nucleobindin-2
(
NUCB2
) is the precursor protein of nesfatin-1, which have a variety of metabolic functions, such as food intake and temperature regulation. In recent years, the potential link between
NUCB2
and the development of multiple cancer was gradually revealed; however, the effects of
NUCB2
on the progression of
glioblastoma
are still unclear.
Methods:
Immunohistochemical assays were performed to explore the
NUCB2
expression levels in 94 samples of
glioblastoma
and corresponding nontumor tissues; patients were divided into
NUCB2
high expression group and low expression group. Clinical analysis related to the clinical features, the potential link between
NUCB2
expression levels, and clinical features were analyzed; the effects of
NUCB2
on cell proliferation and invasion of
glioblastoma
were detected through colony formation and MTT assay, and transwell assay respectively. The possible effects of
NUCB2
on tumor growth and metastasis were measured in mice.
Results:
In this study, we demonstrated that
NUCB2
over-expression was correlated with the high degree of recurrence of patients with
glioblastoma
. Further, we also revealed that
NUCB2
promoted cell proliferation and invasion of
glioblastoma
in vitro
and promoted the growth and metastasis of
glioblastoma
in mice.
Conclusion:
This study provided evidence that
NUCB2
might be a novel therapeutic target of
glioblastoma
.
...
PMID:Nucleobindin-2 Promotes the Growth and Invasion of Glioblastoma. 3169 92